The purpose of this study is to observe and describe treatment patterns, like Overactive Bladder (OAB) treatment discontinuation, switching to other therapies and persistence of OAB therapies in routine clinical practice. This study will also evaluate effectiveness of OAB therapies in routine clinical practice; identify factors associated with effectiveness and persistence of pharmacologic therapies in OAB participants; evaluate the Quality of Life (QoL) and treatment satisfaction of OAB therapies; as well as evaluate health care resource utilization (HCRU) and understand adverse events (AEs), serious adverse events (SAEs) and adverse drug reactions (ADRs) associated with OAB therapies.
This is an observational registry study and will not provide or recommend any treatment; all decisions regarding treatment are made at the sole discretion of the treating physician in accordance with the treating physician's usual practices and all eligible participants will be enrolled in a certain timeframe. OAB participants enrolled in the study will be categorized into one of two treatment groups, but the study does not plan to compare the two treatment groups.
Study Type
OBSERVATIONAL
Enrollment
805
oral
oral
oral
oral
oral
oral
oral
oral
oral
Site KR410008
Daejeon, South Korea
Site KR410009
Incheon, South Korea
Site KR410005
Kangam, South Korea
Site KR410001
Seoul, South Korea
Site KR410002
Seoul, South Korea
Site KR410003
Seoul, South Korea
Site KR410006
Seoul, South Korea
Site KR410007
Seoul, South Korea
Site KR410004
Suwon, South Korea
Site TW158001
Hualien City, Taiwan
...and 5 more locations
Time from treatment initiation to discontinuation of Overactive Bladder (OAB) therapy
Discontinuation will include participants who discontinue mirabegron or antimuscarinics for more than 30 days (defined as the day after the last day of the prior supply to the next dispensing date).
Time frame: Up to 26 weeks
Time from treatment initiation to switching to another OAB therapy or dose
Switching will be defined as a subset of initial mirabegron or antimuscarinics discontinuers who initiated another/different therapy(ies) within the follow-up period or within 30 days of being prescribed the first treatment. Change of treatment to another formulation of the same drug type under the same dosage will not be considered as switching.
Time frame: Up to 26 weeks
Proportion of participants who discontinue OAB treatment
Discontinuation will include participants who discontinue mirabegron or antimuscarinics for more than 30 days (defined as the day after the last day of the prior supply to the next dispensing date).
Time frame: Up to 26 weeks
Proportion of participants who switch to another treatment or dose
Switching will be defined as a subset of initial mirabegron or antimuscarinics discontinuers who initiated another/different therapy(ies) within the follow-up period or within 30 days of being prescribed the first treatment. Change of treatment to another formulation of the same drug type under the same dosage will not be considered as switching.
Time frame: Up to 26 weeks
Change from baseline in Overactive Bladder Questionnaire-Short Form (OAB-Q-SF) score
Overactive Bladder Questionnaire-Short Form (OAB-Q-SF) is a participant-reported instrument consisting of 19 items that assess the degree to which a participant is bothered by OAB symptoms, and the degree of impact of OAB symptoms on daily life. Participants rate each item using a 6-point Likert Scale ranging from "Not at all" to "A very great deal" for the symptom bother items and "none of the time" to "All of the time" for the Health Related Quality of Life (HRQL) items.
Time frame: Baseline, weeks 10-14 and weeks 22-26
Change from baseline in Bladder Assessment Tool (BAT) score
Bladder Assessment Tool (BAT) is a participant-reported instrument consisting of 17 questions regarding the symptoms, bothering, impacts and treatment satisfaction in the past 7 days. Scores range from 0 to 88, a reduction in BAT score indicates an improvement.
Time frame: Baseline, weeks 10-14 and weeks 22-26
Change from baseline in Overactive Bladder Symptom Scores (OABSS) score
Overactive Bladder Symptom Scores (OABSS) is a participant-reported instrument consisting of 4 questions regarding daytime frequency, nocturia, urgency, and urgency incontinence; evaluates relevant symptoms from the participant's viewpoint. Scores range from 0 to 15 with a lower score indicating a mild presentation of overactive bladder syndrome and a higher score indicating moderate to severe presentation of overactive bladder syndrome.
Time frame: Baseline, weeks 10-14 and weeks 22-26
Change from baseline in Treatment Satisfaction-Visual Analog Scale (TS-VAS) score
Treatment Satisfaction-Visual Analog Scale (TS-VAS) is a quantitative instrument assessing participant improvement in participants with OAB. A score of 10 on the TS-VAS indicates complete satisfaction, whereas a positive change from baseline indicates improvement.
Time frame: Baseline, weeks 10-14 and weeks 22-26
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: Demographic Information
Demographic information will be collected from participants for analysis.
Time frame: Baseline (up to Day 0)
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: OAB Medical History
OAB medical history will be collected from participants for analysis.
Time frame: Baseline (up to Day 0)
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: History of prior drug treatment for OAB
History of prior drug treatment for OAB will be collected from participants for analysis.
Time frame: Baseline (up to Day 0)
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: Medical history
Medical history will be collected from participants for analysis.
Time frame: Baseline (up to Day 0)
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: Concomitant medication information
Concomitant medication will be collected from participants for analysis.
Time frame: Up to 26 weeks
Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: Concomitant medical conditions
Participants medical history will be collected from participants for analysis.
Time frame: Up to 26 weeks
Health Care Resource Utilization (HCRU) related to the management of OAB
Participant information will be collected by the investigator or designee via the Healthcare Resource Utilization (HCRU) Worksheet at each visit and the data will be retrieved electronically via the electronic case report form (eCRF). The HCRU worksheet consists of 7 questions related to the participants history and treatment of OAB.
Time frame: Up to 26 weeks
Safety assessed by Adverse Events (AEs)
An AE is any untoward medical occurrence in a patient or clinical study patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a product, whether or not considered related to the product. Pre-existing conditions that worsen during a study are to be reported as AEs.
Time frame: Up to 26 weeks
Safety assessed by Serious Adverse Events (SAEs)
Adverse event (AE) is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event.
Time frame: Up to 26 weeks
Safety assessed by Adverse Drug Reaction (ADR)
An ADR is defined as any noxious and unintended response associated with the use of a drug in humans, at any dose, where a causal relationship (drug-event) is at least a reasonable possibility.
Time frame: Up to 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.